Excerpted and adapted from:
Fleischmann RM, Wagner F, Kivitz AJ, et al. Safety, tolerability, and pharmacodynamics of ABT-122, a tumor necrosis factor and interleukin 17–targeted dual variable domain immunoglobulin, in patients with rheumatoid arthritis. Arthritis Rheumatol. 2017 Dec;69(12):2283–2291.
Related Articles
Upadacitinib Meets Study Endpoints to Treat RA
A recent clinical trial found that upadacitinib may effectively reduce disease activity at Week 12 for patients with moderate to severe rheumatoid arthritis…
FDA Warns ‘Don’t Use Tramadol in Children’ & More
New studies show ABT-494 is an effective alternative to anti-TNF alpha agents, as well as methotrexate, for RA. Also, the FDA issued a warning against using tramadol for young patients due to their increased risk of respiratory side effects…
Dual Certification: Is 1 Head Better Than 2?
“Hi, I’m Dr. Kumar, and I’m an allergist,” is something I sometimes fumble when I introduce myself to confused rheumatology patients, before I quickly correct myself with, “… well, I’m also a rheumatologist.” There’s a moment of slight embarrassment that I crossed my circuits, but otherwise I’m proud to say I’m certified in both. This…
TNF Blockade for SLE
Reckless approach versus missed opportunity?